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of therapeutic options for CHC patients. Some of them
have shown promising results in clinical trials. A number
of HCV polymerase inhibitors are in phase I or II trials
and entry inhibitors are under development. Two HCV
NS3 4A protease inhibitors (PIs) have completed phase
III studies. Data from phase 2 studies have shown that
a substantial number of HCV-1 patients could achieve an
SVR with DAA plus Peg-IFN/RBV for even 12 or 24 weeks.
Phase III studies of Boceprevir or Telaprevir demonstrated
PI/Peg-IFN/RBV (with or without “lead in” pretreatment)
based on strategy of week 4 response-guided therapy
could dramatically improve the SVR rates to 63 75% in
HCV-1 treatment-naive patients. In addition, the boceprevir
regimens consistently achieved SVR rates of approximately
40% to 50% among the more difﬁcult-to-treat patients, such
as blacks and previous nonresponders. However, subgroup
analysis demonstrated that the beneﬁts of adding boceprevir
was only observed among patients carrying unfavorable IL28
genotype. Therefore, excitement over these impressive
results needs to be tempered by the complexity of the
regimens, the high rates of anemia, and the development of
boceprevir resistance-associated variants, especially among
treatment-experienced patients.
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Antimicrobial resistance is getting a challenge and threat to
public healthcare, which was announced as one of the most
severe public healthcare crisis by WHO. Strategies for the
containment of AMR include resistant surveillance, resistant
mechanism study, prudent application of antimicrobial
agents and new antibiotic development, etc. It is very
important to clinicians to prescribe antibiotics referring
to the bacterial resistant monitoring results, and resistant
mechanism researches would elucidate the biological basis
of antibiotic resistance and provide basic information for
overcoming AMR and ﬁnding new antibiotic target. The
national and local bacterial resistant surveillance networks
have been set up and the researches on the resistant
mechanisms have achieved much valuable results.
1. Antibiotic resistant surveillance networks in China:
Companying with the social-economic development, health-
care improvement, lifespan elongation and communicable
disease decrement, infections, especially nosocomial
infections and infections with resistant germs are emerging
as one of the major morbidity and mortality in
China. Bacterial resistance has got also an unavoidable
public health problem. It is becoming a consensus of
clinician, microbiologist, pharmacist, healthcare ofﬁcials
and pharmaceutical companies to investigate bacterial
resistance, study resistant mechanisms and ﬁnd out
effective handling measures. Ofﬁcial facilities, medical
institutions and pharmaceutical companies conducted most
of the bacterial resistant surveillance.
Ofﬁcial bacterial resistance surveillance: The national and
provincial antimicrobial resistant surveillance networks
were established after 2005, the national network is named
Mohnarin (MOH national antibacterial resistant investigation
net ) because of the initiation of MOH in 2005, the
major mission of Mohnarin is to get national bacterial
resistant information and assist the antimicrobial agent
administration in China. This network was composed of some
150 tertiary hospitals across the country. All the hospitals
conduct surveillance by a common protocol, but each
hospital do not need to modify its own routine daily clinical
microbiological schedule, such as bacterial identiﬁcation,
antibiotic sensitive panel. The investigational results are
submitted to Mohnarin Center for data analysis. WHONET
software is employed for data processing. For promotion
the surveillance quality, there are some training course
and workshop focusing on the QC/QA and Whonet software
use. Mohnarin should generate yearly report to MOH. By
the regulation of MOH, some provinces have their own
AMR surveillance network, which consist of both tertiary
hospitals and primary hospitals. Mohnarin is not only the
largest network and but also the high quality one.
Medical institution bacterial resistance surveillance: Most
of tertiary hospitals in China have their regular or irregular
bacterial resistant surveillance carried out by their clinical
microbiology units or nosocomial monitoring facilities.
Pharmaceutical company bacterial resistant surveillance:
For the purpose of getting bacterial resistance to some
special antibacterial agent, some pharmaceutical company
occasionally organized bacterial resistant surveillance.
Although with participation of scientiﬁc members, the
business aim makes the clinical value of the results is
limited.
2. Prevalence of bacterial resistance: By the results
of Mohnarin 2008, 160513 bacterial isolates and their
antibacterial susceptibility data were collected during the
survey period in 89 tertiary hospitals, which included
50856 (31.68%) Gram-positive and 106957(68.32%) Gram-
negative bacterial strains. Staphylococcus (32378 strains),
enterococcus (12127 strains) and streptococcus (5138
strains) were the top three gram-positive isolates, while
Escherichia coli (26957 strains), Pseudomonas aeruginosa
(18347 strains) and Klebsiella pneumoniae (16396 strains)
were the most common Gram-negative isolates. Methicillin-
resistant Staphylococcus aureus (MRSA) and Staphylococcus
epidermidis were 67.6% and 83.2%, respectively; 3.8%
of Streptococcus pneumoniae was penicillin resistant.
Glycopeptides resistant enterococcus was rare. More than
40% of E. coli and other enterobacteria were resistant to
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most of the agents monitored, quinolone-resistant E. coli
was over 70% and 56.0% of the germ was extended spectrum
b-lactamase (ESBL) positive, especially, the resistant rate of
E. coli against the third and fourth generation cephalosporin
(including ceftazidime) was higher than 60%. 24.8%-
41.7% of glucose non-fermented bacteria were resistant
to meropenem, and the resistant rate of Acinetobacter
baumannii overtook that of P. aeruginosa.
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Background: Chikungunya, a vector-borne disease, has
recently re-emerged. Not only has Chikungunya caused
major public health problems in several regions of the
world but its outbreaks have also had a signiﬁcant impact on
the global economy. Chikungunya is caused by Chikungunya
virus (CHIKV) which is transmitted by Aedes mosquitoes as
its major vectors. Clinical manifestations of Chikungunya
include high grade fever, severe arthralgia, myalgia and
maculopapular rash.
Aims: This study has reviewed re-emergence of Chikungunya
virus especially in Asia and Africa.
Methods: Available information on Chikungunya virus
infection was selected from our research in Thailand and
the literature.
Results and Conclusions: CHIKV was ﬁrst isolated in
Tanzania in 1952. Since then, numerous outbreaks have
been reported in the tropical countries of Asia and Africa.
Phylogenetic analysis based on E1 gene sequences has
identiﬁed three genotypes of CHIKV, East Central and
Southeast African (ECSA), West African and Asian genotypes.
CHIKV has been circulating in several countries in Asia and
was initially isolated in Thailand in 1958. From 1990 to
2005, the frequency of Chikungunya outbreaks in Asia has
declined. In 2005, reemergence of Chikungunya caused by
the ECSA strain was conﬁrmed on Reunion Island and CHIKV
has rapidly spread to India in 2007. Several genome analyses
have shown that mutation of CHIKV at position A226V of
the E1gene increases transmissibility of CHIKV by Aedes
albopictus mosquitoes. Thailand has experienced several
outbreaks of Chikungunya since September 2008. Studies
have shown that Chikungunya was introduced to the south
of Thailand from India via Sri Lanka and Indonesia and was
caused by the ECSA strain harboring the A226V mutation of
the E1 gene identical to the strains isolated from Reunion
Island. The outbreaks were mostly conﬁned to the south of
the country where Para rubber plantations are abundant and
Aedes albopictus mosquitoes are endemic. The outbreaks
reached a peak in 2009 and have gradually decreased
since 2010. These Chikungunya outbreaks have had a major
impact on public health and Thailand’s economy.
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New treatments are urgently needed to combat the growing
number of dengue fever cases in more than 100 countries
around the world where the virus is endemic. The infected
cases exhibit a broad spectrum of clinical symptoms, ranging
from being fully asymptomatic to causing life-threatening
conditions like dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS). There are no effective antivirals or
safe vaccines available to protect against the four closely
related but antigenically distinct dengue viruses.
Several compounds or antibodies that target viral entry
or viral replication have been reported, however their
progression to the clinic has been somewhat challenging
because there are no animal models that suitably mimic the
spectrum of human disease. A viremia model in AG129 mice
has been shown to be useful for testing compounds and
biologics. Additionally, Antibody Dependent Enhancement
(ADE) infection by DENV in AG129 mice, where passive
immunity using low concentration of anti-DENV antibody,
exacerbated dengue disease severity with small intestinal
hemorrhage and decreased survival time post-infection have
been established. These advances, together with efforts to
introduce “repurposed” drugs such as chloroquine to treat
dengue can accelerate antiviral therapies for dengue fever.
The current status of dengue antiviral development will be
reviewed and some recent data with “repurposed” drugs
will be presented.
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The ongoing saga over the name of the NDM-1 gene obscures,
sometimes deliberately so, the over aching problems of
holistically negating the continued spread of antibiotic
resistance. Genetic ﬂuidity and plasticity aside, man’s
paradoxical behaviour both nationally and internationally
has spawned and aided and abetted “superbugs” that is
likely to herald the end of conventional treatment of
infectious diseases and plunge future generations into the
uncertainty of clinical outcomes more akin to the 19th
century. Patently, we are lacking global responsibility and
the means to deal with countries which continuously ignore
guidelines from the WHO and others.
This brief synopsis will not only outline the epidemiology of
NDM-1 and its genetics but also key risk factors in its spread
both throughout Southern Asia and globally.
